The acquisition adds YUPELRI® and diversified assets, providing immediate and growing cash flows, with a $929 million deal financed through innovative non-recourse structures. The transaction is expected to close in H2 2026, supporting long-term growth and shareholder value.Original document: Zymew…
The acquisition adds YUPELRI® and diversified assets, providing immediate and growing cash flows, with a $929 million deal financed through innovative non-recourse structures. The transaction is expected to close in H2 2026, supporting long-term growth and shareholder value.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.